A Venture Studio with Big Pharma Backing Seeks to Fix Drug Development with AI
In This Episode
Mati Gill, CEO of AION Labs, sits down with Amar Drawid to discuss how the AI venture studio works with its Big Pharma partners.
- The biggest drug development hurdles the industry faces.
- Challenges to attract academics, entrepreneurs, and life sciences professionals with the best solutions to build new companies.
Transcript
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Heading 6
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
Block quote
Ordered list
- Item 1
- Item 2
- Item 3
Unordered list
- Item A
- Item B
- Item C
Bold text
Emphasis
Superscript
Subscript
Our Host
Dr. Amar Drawid
Dr. Amar Drawid, an industry veteran who has worked in data science leadership with top biopharmaceutical companies. He explores the evolving use of AI and data science with innovators working to reshape all aspects of the biopharmaceutical industry from the way new therapeutics are discovered to how they are marketed.
Our Speaker
Mati Gill
Mati Gill, CEO of AION Labs, brings extensive experience in the pharmaceutical and biotech industries. Prior to leading AlON Labs, Mati spent 11 years at Teva Pharmaceuticals, where he served as the Head of Government Affairs, Corporate and International Markets. During his tenure at Teva, he developed the company's innovative strategy and built a robust network of partnerships. Mati holds an MBA and a BA in Law from Reichman University, underscoring his expertise in both business and legal aspects of the industry.
.avif)
.avif)
.avif)
.avif)
.avif)